EMA looks set to give latest Comirnaty jab the nod
The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended authorizing a version of BioNTech (Nasdaq: BNTX) and Pfizer’s (NYSE: PFE) Comirnaty COVID-19 vaccine targeting the Omicron XBB.1.5 subvariant.
This adapted vaccine - known as Comirnaty Omicron XBB.1.5 - is to be used for preventing COVID-19 in adults and children from six months of age.
In line with previous recommendations by the EMA and the European Center for Disease Prevention and Control, adults and children from five years who require vaccination should have a single dose, irrespective of their COVID-19 vaccination history.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze